Introduction {#section5-1756284818818326}
============

Irritable bowel syndrome (IBS) is a common gastrointestinal (GI) disorder that affects 10--15% of the United States (US) population,^[@bibr1-1756284818818326]^ with a higher prevalence among women and patients under 50 years of age.^[@bibr2-1756284818818326]^ IBS is characterized by recurrent abdominal pain and altered bowel habits; bloating and distension frequently coexist. Symptoms are frequently chronic, which can negatively impact patients' quality of life.^[@bibr3-1756284818818326],[@bibr4-1756284818818326]^

Diagnosing IBS can be challenging due to the nonspecific nature of symptoms, overlapping upper and lower abdominal symptoms, and the frequent presence of somatic and psychological comorbidities.^[@bibr3-1756284818818326]^ The Rome IV guidelines state that diagnostic tests may be appropriate in the evaluation of a patient with IBS symptoms.^[@bibr5-1756284818818326]^ However, no validated algorithm for diagnostic tests exists. The Rome criteria are most often used during IBS diagnosis, and clinical guidelines on the management of IBS have been developed to help improve and standardize treatment.^[@bibr6-1756284818818326][@bibr7-1756284818818326]--[@bibr8-1756284818818326]^ Despite these guidelines, there remains low awareness and little consensus on the use of diagnostic tests and surgical procedures in IBS.^[@bibr9-1756284818818326],[@bibr10-1756284818818326]^ Furthermore, although surgery has no role in the recommended treatment approach for IBS,^[@bibr8-1756284818818326]^ multiple studies have reported that this patient population is predisposed to unnecessary surgical procedures,^[@bibr11-1756284818818326][@bibr12-1756284818818326][@bibr13-1756284818818326]--[@bibr14-1756284818818326]^ suggesting a disconnect between the recommended best practices and real-world management of IBS.

IBS causes a significant burden on healthcare systems, due in part to the high level of healthcare resource utilization (HRU) associated with IBS.^[@bibr15-1756284818818326]^ Direct medical costs attributed to IBS in the US, excluding prescription and over-the-counter medicines, were estimated at US \$1.5--\$10 billion per year in 2005.^[@bibr16-1756284818818326]^ A portion of these costs may be related to unnecessary^[@bibr17-1756284818818326]^ and high-frequency tests,^[@bibr14-1756284818818326]^ although few studies have assessed the factors underlying frequent tests and procedures among patients with IBS. A claims study (2001--2012) reported large regional variation in levels of HRU among patients with IBS in the US;^[@bibr15-1756284818818326]^ however, the reasons for the differences are unclear. A systematic review and meta-analysis found that certain comorbidities, such as depression and anxiety, are prevalent among this patient population, which may contribute to higher HRU including tests and procedures.^[@bibr18-1756284818818326]^ However, prior studies have not adequately evaluated the demographic and clinical factors which influence the use, and overuse, of diagnostic tests and procedures among IBS patients.

This study assessed the demographic and clinical factors associated with high test frequency among adults with IBS in the US. We hypothesized that patients with more comorbid conditions overlapping with IBS, or psychological disorders such as anxiety, depression, or somatization, would be likely to undergo relatively frequent tests/diagnostic procedures.

Methods {#section6-1756284818818326}
=======

Data source {#section7-1756284818818326}
-----------

Data were derived from the Truven Health Analytics MarketScan^®^ databases (1 January 2001 to 31 December 2012, the latest period with US state-level data), a large retrospective US commercial claims database that is nationally representative of Americans with employer-provided health insurance and Medicaid.^[@bibr19-1756284818818326]^ The database contains information regarding patient demographics, health plan enrollment history, medical diagnoses, procedures performed, dates and places of service, and payment amounts as well as prescription drug claims for over 25 million covered lives annually.

Patient selection and groups {#section8-1756284818818326}
----------------------------

Patients were included in the study if they (1) had at least two separate and distinct diagnoses for IBS \[International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis code 564.1x\] recorded on different dates between 1 January 2001 and 31 December 2012; (2) had ⩾12 months of continuous healthcare plan enrollment before and after the first recorded IBS diagnosis; and (3) were aged ⩾18 years on the date of the first recorded IBS diagnosis, with no upper age limit.

Patients were categorized into three groups based on the frequency of tests/procedures received during the 2-year study period: the high-count group (⩾3 tests/procedures), the moderate-count group (1--2 tests/procedures), and the zero-count group (0 tests/procedures). Tests were summarized by category level (i.e. colonoscopy, anoscopy, Sitzmark test) and patients were permitted to have the same procedure once per day; the same test on different days or multiple tests with separate codes on the same day were considered to be separate procedures. Appendix A contains a list of included GI tests/procedures along with their corresponding diagnostic and procedural codes used to search the claims database. Physician specialty was recorded, identified based on a corresponding annotation in the data.

This study was not subject to review by an Institutional Review Board, and no informed consent was needed, as ethics approval was not required for this national database study.

Study period and measures {#section9-1756284818818326}
=========================

The study period was defined as the 2-year period surrounding the first recorded IBS diagnosis (i.e. 1 year before and on/after the first IBS diagnosis date). The index date was defined as the date of the first recorded IBS diagnosis. Data collected during the study period included patient demographics, including age at IBS diagnosis, sex, region of residence, and insurance plan type; clinical characteristics, including modified Charlson--Quan comorbidity index (CCI; a composite measure of patient's health)^[@bibr20-1756284818818326]^ and IBS-related comorbidities \[e.g. dyspepsia, gastroesophageal reflux disease (GERD), interstitial cystitis, anxiety, depressive disorders, and somatization; see Appendix B; note that constipation, while clinically considered an IBS symptom, had to be computed as a comorbidity, as at the time of the study there was no specific coding for IBS with constipation\]; and HRU, including all-cause medical visits stratified by provider type (e.g. family practice, internal medicine, emergency medicine), intestinal-related emergency department (ED) visits, and inpatient admissions. IBS medical procedures and tests were identified in the database using ICD-9-CM and Current Procedural Terminology (CPT) codes (see Appendix A). Types of healthcare plans included preferred provider organization (PPO), health maintenance organization (HMO), comprehensive coverage (i.e. total coverage for healthcare-related charges), point of service (POS)/POS with capitation, consumer-directed health plan (CDHP)/high-deductible health plan (HDHP), exclusive provider organization (EPO), and 'unknown.'

Statistical analysis {#section10-1756284818818326}
====================

Pairwise comparisons of patient demographic and clinical characteristics were conducted across the high-, moderate-, and low-count groups using Chi-squared tests for categorical variables and Wilcoxon rank-sum tests for continuous variables. Univariate and multivariate logistic regression models, comparing the high- and moderate-count groups, were estimated to identify factors associated with more frequent use of tests/procedures. The multivariate regression models used stepwise selection to choose the most relevant variables while generating a parsimonious model. Results were reported as an odds ratio (OR) and corresponding 95% confidence interval (CI). The proportions of patients with different combinations of comorbid conditions were summarized for the zero-, moderate-, and high-count groups. A *p* value of 0.05 was used to determine statistical significance.

Results {#section11-1756284818818326}
=======

Demographic and clinical characteristics of patients with IBS {#section12-1756284818818326}
-------------------------------------------------------------

A total of 201,322 IBS patients met the inclusion criteria ([Figure 1](#fig1-1756284818818326){ref-type="fig"}), with 83,852 (42%), 70,577 (35%), and 46,892 (23%) patients in the high-, moderate-, and zero-count test groups, respectively ([Figure 2](#fig2-1756284818818326){ref-type="fig"}). Across all groups, patients were predominantly from the south (40.5--43.5%, including the following US states: Alabama, North Carolina, South Carolina, Georgia, Texas, Mississippi, Louisiana, Florida) and had PPO insurance (57.0--59.0%; [Table 1](#table1-1756284818818326){ref-type="table"}).

![Sample selection of patients with IBS diagnosis in the United States.\
Patients in the high-count group had ⩾3 tests/procedures in the 2-year study period, those in the moderate-count group had 1--2 tests/procedures, and those in the zero-count group had no tests/procedures. IBS diagnosis was identified by a claim with ICD-9 code 564.1x.\
IBS, irritable bowel syndrome; ICD, International Classification of Diseases, ninth revision; *N*, number.](10.1177_1756284818818326-fig1){#fig1-1756284818818326}

![Number of diagnostic tests/procedures during the 2-year study period and definition of study cohorts.\
*N*, number.](10.1177_1756284818818326-fig2){#fig2-1756284818818326}

###### 

Comparison of demographic and clinical characteristics among IBS patients stratified by multiple test/procedure counts.^[a](#table-fn2-1756284818818326){ref-type="table-fn"},[b](#table-fn3-1756284818818326){ref-type="table-fn"}^

![](10.1177_1756284818818326-table1)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                              High-count group      Moderate-count group   Zero-count group      *p* value^[c](#table-fn4-1756284818818326){ref-type="table-fn"}^\   *p* value^[c](#table-fn4-1756284818818326){ref-type="table-fn"}^\   *p* value^[c](#table-fn4-1756284818818326){ref-type="table-fn"}^\
                                                                                                                                                                                                                                 High *versus* zero multiple test/ procedure count                   Moderate *versus* zero multiple test/ procedure count               High *versus* moderate multiple test/procedure count
  ----------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------- ---------------------- --------------------- ------------------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------
  **Demographics**                                                                                                                                                                                                                                                                                                                                                       

   Age,^[d](#table-fn5-1756284818818326){ref-type="table-fn"}^ mean ± SD                                                                                      50.6 ± 15.4           49.5 ± 15.1            46.8 ± 15.6           \<0.0001                                                            \<0.0001                                                            \<0.0001

   Female, *n* (%)                                                                                                                                            66,629 (79.5)         54,102 (76.7)          34,718 (74.0)         \<0.0001                                                            \<0.0001                                                            \<0.0001

   Male, *n* (%)                                                                                                                                              17,224 (20.5)         16,475 (23.3)          12,174 (26.0)         \<0.0001                                                            \<0.0001                                                            \<0.0001

  **Region, *n* (%)**                                                                                                                                                                                                                                                                                                                                                    

   South                                                                                                                                                      36,191 (43.2)         29,235 (41.4)          19,002 (40.5)         \<0.0001                                                            0.0021                                                              \<0.0001

   North-central                                                                                                                                              22,831 (27.2)         18,334 (26.0)          12,501 (26.7)         0.0265                                                              0.0093                                                              \<0.0001

   West                                                                                                                                                       13,512 (16.1)         14,341 (20.3)          9931 (21.2)           \<0.0001                                                            0.0004                                                              \<0.0001

   North-east                                                                                                                                                 11,319 (13.5)         8667 (12.3)            5458 (11.6)           \<0.0001                                                            0.0009                                                              \<0.0001

  **Insurance plan type, *n* (%)**                                                                                                                                                                                                                                                                                                                                       

   PPO                                                                                                                                                        47,834 (57.0)         40,642 (57.6)          27,684 (59.0)         \<0.0001                                                            \<0.0001                                                            0.0325

   HMO                                                                                                                                                        11,683 (13.9)         11,035 (15.6)          7584 (16.2)           \<0.0001                                                            0.0134                                                              \<0.0001

   Comprehensive cover                                                                                                                                        10,946 (13.1)         7784 (11.0)            4339 (9.3)            \<0.0001                                                            \<0.0001                                                            \<0.0001

   POS/POS with capitation                                                                                                                                    8627 (10.3)           7339 (10.4)            4527 (9.7)            0.0003                                                              \<0.0001                                                            0.4781

   CDHP/HDHP                                                                                                                                                  1796 (2.1)            1453 (2.1)             1135 (2.4)            0.0011                                                              \<0.0001                                                            0.2570

   EPO                                                                                                                                                        1241 (1.5)            889 (1.3)              620 (1.3)             0.0209                                                              0.3510                                                              0.0002

   Unknown                                                                                                                                                    1726 (2.1)            1435 (2.0)             1003 (2.1)            0.3282                                                              0.2132                                                              0.7283

  **Year of earliest IBS diagnosis, *n* (%)**                                                                                                                                                                                                                                                                                                                            

   2002                                                                                                                                                       3369 (4.0)            3454 (4.9)             2056 (4.4)            0.0014                                                              \<0.0001                                                            \<0.0001

   2003                                                                                                                                                       4491 (5.4)            4173 (5.9)             2363 (5.0)            0.0138                                                              \<0.0001                                                            \<0.0001

   2004                                                                                                                                                       7214 (8.6)            6528 (9.2)             3934 (8.4)            0.1846                                                              \<0.0001                                                            \<0.0001

   2005                                                                                                                                                       5833 (7.0)            5348 (7.6)             3149 (6.7)            0.0988                                                              \<0.0001                                                            \<0.0001

   2006                                                                                                                                                       5358 (6.4)            4646 (6.6)             3078 (6.6)            0.2187                                                              0.8984                                                              0.1245

   2007                                                                                                                                                       10,387 (12.4)         9088 (12.9)            5953 (12.7)           0.1063                                                              0.3617                                                              0.0039

   2008                                                                                                                                                       9096 (10.8)           7441 (10.5)            4878 (10.4)           0.0125                                                              0.4416                                                              0.0539

   2009                                                                                                                                                       10,588 (12.6)         8926 (12.6)            6319 (13.5)           \<0.0001                                                            \<0.0001                                                            0.9047

   2010                                                                                                                                                       12,564 (15.0)         9528 (13.5)            6923 (14.8)           0.2848                                                              \<0.0001                                                            \<0.0001

   2011                                                                                                                                                       14,944 (17.8)         11,440 (16.2)          8237 (17.6)           0.2455                                                              \<0.0001                                                            \<0.0001

   2012                                                                                                                                                       9 (0.0)               5 (0.0)                2 (0.0)               0.3476                                                              0.7099                                                              0.4531

  **Modified Charlson--Quan comorbidity index,^[a](#table-fn2-1756284818818326){ref-type="table-fn"}^ mean ± SD**                                             2.2 ± 2.2             1.4 ± 1.6              1.1 ± 1.3             \<0.0001                                                            \<0.0001                                                            \<0.0001

  **IBS-related comorbidities,^[a](#table-fn2-1756284818818326){ref-type="table-fn"},[e](#table-fn6-1756284818818326){ref-type="table-fn"}^*n* (%)**                                                                                                                                                                                                                     

   Anxiety                                                                                                                                                    17,116 (20.4)         10,933 (15.5)          7388 (15.8)           \<0.0001                                                            0.2211                                                              \<0.0001

   Depressive disorders                                                                                                                                       19,733 (23.5)         12,523 (17.7)          8211 (17.5)           \<0.0001                                                            0.3044                                                              \<0.0001

   Somatization                                                                                                                                               203 (0.2)             52 (0.1)               31 (0.1)              \<0.0001                                                            0.6326                                                              \<0.0001

   Migraines                                                                                                                                                  10,408 (12.4)         6051 (8.6)             3823 (8.2)            \<0.0001                                                            0.0109                                                              \<0.0001

   Interstitial cystitis                                                                                                                                      1594 (1.9)            656 (0.9)              266 (0.6)             \<0.0001                                                            \<0.0001                                                            \<0.0001

   Fibromyalgia                                                                                                                                               12,598 (15.0)         7099 (10.1)            3988 (8.5)            \<0.0001                                                            \<0.0001                                                            \<0.0001

   Chronic fatigue                                                                                                                                            1902 (2.3)            1213 (1.7)             779 (1.7)             \<0.0001                                                            0.4553                                                              \<0.0001

   Dyspareunia                                                                                                                                                1494 (1.8)            802 (1.1)              351 (0.7)             \<0.0001                                                            \<0.0001                                                            \<0.0001

   Dyspepsia                                                                                                                                                  10,864 (13.0)         4095 (5.8)             1224 (2.6)            \<0.0001                                                            \<0.0001                                                            \<0.0001

   GERD                                                                                                                                                       33,893 (40.4)         16,964 (24.0)          7105 (15.2)           \<0.0001                                                            \<0.0001                                                            \<0.0001

   Constipation                                                                                                                                               21,437 (25.6)         10,555 (15.0)          3635 (7.8)            \<0.0001                                                            \<0.0001                                                            \<0.0001

  **Number of comorbid conditions,^[a](#table-fn2-1756284818818326){ref-type="table-fn"},[e](#table-fn5-1756284818818326){ref-type="table-fn"}^ mean ± SD**   4.3 ± 2.3             2.7 ± 1.9              1.7 ± 1.6             \<0.0001                                                            \<0.0001                                                            \<0.0001

  **Average copayment for medical service (USD),^[a](#table-fn2-1756284818818326){ref-type="table-fn"}^ mean ± SD**                                                                                                                                                                                                                                                      

   Inpatient                                                                                                                                                  102.8 ± 524.5         109.0 ± 476.9          96.4 ± 300.7          \<0.0001                                                            0.3721                                                              \<0.0001

   Outpatient                                                                                                                                                 8.6 ± 30.3            8.3 ± 30.2             6.3 ± 37.5            \<0.0001                                                            \<0.0001                                                            \<0.0001

   Emergency department                                                                                                                                       37.2 ± 54.7           37.8 ± 55.2            38.3 ± 55.0           0.8105                                                              0.6019                                                              0.2880

   Office                                                                                                                                                     15.1 ± 25.2           14.7 ± 15.2            14.6 ± 19.7           0.0003                                                              0.2829                                                              0.0042

   Other                                                                                                                                                      13.1 ± 65.6           14.4 ± 60.2            9.6 ± 57.2            \<0.0001                                                            0.0001                                                              0.9918

  **Average deductible for medical service (USD),^[a](#table-fn2-1756284818818326){ref-type="table-fn"}^ mean ± SD**                                                                                                                                                                                                                                                     

   Inpatient                                                                                                                                                  113.3 ± 377.4         148.0 ± 503.2          181.7 ± 780.8         \<0.0001                                                            0.2803                                                              \<0.0001

   Outpatient                                                                                                                                                 36.4 ± 100.4          51.6 ± 139.5           38.5 ± 109.7          \<0.0001                                                            \<0.0001                                                            0.2956

   ED                                                                                                                                                         30.5 ± 123.8          44.4 ± 156.9           53.0 ± 174.5          \<0.0001                                                            \<0.0001                                                            \<0.0001

   Office                                                                                                                                                     10.7 ± 19.1           14.4 ± 25.6            17.2 ± 31.0           \<0.0001                                                            \<0.0001                                                            \<0.0001

   Other                                                                                                                                                      45.4 ± 167.3          66.3 ± 209.6           38.2 ± 172.6          0.2128                                                              \<0.0001                                                            \<0.0001

  **Number of medical visits by provider type,^[a](#table-fn2-1756284818818326){ref-type="table-fn"}^ mean ± SD**                                                                                                                                                                                                                                                        

   Family practice                                                                                                                                            6.5 ± 10.6            4.5 ± 7.3              3.9 ± 6.4             \<0.0001                                                            \<0.0001                                                            \<0.0001

   Internal medicine (NEC)                                                                                                                                    5.6 ± 10.0            3.2 ± 5.9              2.4 ± 4.8             \<0.0001                                                            \<0.0001                                                            \<0.0001

   Gastroenterology                                                                                                                                           3.3 ± 4.3             1.4 ± 2.0              0.4 ± 1.1             \<0.0001                                                            \<0.0001                                                            \<0.0001

   Medical doctor (NEC)                                                                                                                                       3.8 ± 12.7            2.4 ± 8.4              1.8 ± 7.0             \<0.0001                                                            \<0.0001                                                            \<0.0001

   Multi-specialty physician group                                                                                                                            2.3 ± 9.5             1.6 ± 6.7              1.2 ± 5.4             \<0.0001                                                            \<0.0001                                                            \<0.0001

   Emergency medicine                                                                                                                                         1.1 ± 3.2             0.4 ± 1.4              0.3 ± 1.1             \<0.0001                                                            \<0.0001                                                            \<0.0001

  **At least one gastroenterology visit,^[a](#table-fn2-1756284818818326){ref-type="table-fn"}^*n* (%)**                                                      56,022 (66.8)         35,095 (49.7)          9682 (20.6)           \<0.0001                                                            \<0.0001                                                            \<0.0001

  **Intestinal-related medical care** ^[a](#table-fn2-1756284818818326){ref-type="table-fn"}^                                                                                                                                                                                                                                                                            

   ED visits, mean ± SD                                                                                                                                       0.2 ± 0.6             0.1 ± 0.2              0.0 ± 0.2             \<0.0001                                                            \<0.0001                                                            \<0.0001

    At least one ED visit, *n* (%)                                                                                                                            9639 (11.5)           3149 (4.5)             941 (2.0)             \<0.0001                                                            \<0.0001                                                            \<0.0001

   IP admissions, mean ± SD                                                                                                                                   0.2 ± 0.6             0.0 ± 0.2              0.0 ± 0.1             \<0.0001                                                            \<0.0001                                                            \<0.0001

    At least one IP admission, *n* (%)                                                                                                                        12,040 (14.4)         1961 (2.8)             700 (1.5)             \<0.0001                                                            \<0.0001                                                            \<0.0001

  **Federal qualified health centers per 100,000 residents,^[f](#table-fn7-1756284818818326){ref-type="table-fn"}^ mean ± SD**                                3.6 ± 16.2            3.7 ± 17.0             3.7 ± 16.5            \<0.0001                                                            \<0.0001                                                            \<0.0001

  **Provider density,^[f](#table-fn7-1756284818818326){ref-type="table-fn"}^ mean ± SD**                                                                                                                                                                                                                                                                                 

   Number of hospitals per 100,000 residents                                                                                                                  2.3 ± 9.1             2.3 ± 7.6              2.4 ± 7.1             0.0720                                                              0.1535                                                              0.7583

   Number of active MDs per 1000 residents                                                                                                                    3.3 ± 8.7             3.2 ± 2.6              3.3 ± 10.1            \<0.0001                                                            0.5261                                                              \<0.0001

   Number of gastroenterologists per 1000 residents                                                                                                           0.1 ± 0.6             0.2 ± 0.7              0.2 ± 0.7             0.0003                                                              0.0551                                                              \<0.0001

   Number of general internal med per 1000 residents                                                                                                          0.6 ± 3.2             0.6 ± 3.7              0.6 ± 4.0             \<0.0001                                                            0.6356                                                              \<0.0001

  **Neighborhood demographics,^[f](#table-fn7-1756284818818326){ref-type="table-fn"}^ mean ± SD**                                                                                                                                                                                                                                                                        

   % in poverty                                                                                                                                               14.6 ± 5.1            14.5 ± 5.0             14.5 ± 5.0            0.0614                                                              0.1013                                                              \<0.0001

   Median household income (USD)                                                                                                                              50,940.6 ± 12,685.9   50,869.4 ± 12,538.3    51,069.4 ± 12,567.7   0.0030                                                              0.0026                                                              0.8505

   % with college-level education                                                                                                                             29.5 ± 10.1           29.4 ± 10.1            29.6 ± 10.2           0.0376                                                              0.0157                                                              0.6269

   % without high school-level education                                                                                                                      14.5 ± 5.3            14.6 ± 5.4             14.5 ± 5.4            0.0021                                                              0.5940                                                              \<0.0001
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CDHP, consumer-directed health plan; ED, emergency department; EPO, exclusive provider organization; GERD, gastroesophageal reflux disease; HDHP, high-deductible health plan; HMO, health maintenance organization; IBS, irritable bowel syndrome; IP, inpatient; Med, medicine; MD, medical doctor; *N*, number; NEC, not elsewhere classifiable; POS, point of service; PPO, preferred provider organization; SD, standard deviation; USD, United States dollars.

Evaluated during the 2-year study period which includes the 12 months prior to the earliest IBS diagnosis and the 12 months following the earliest IBS diagnosis.

See [Supplemental File-Appendix A](https://journals.sagepub.com/doi/suppl/10.1177/1756284818818326) for a comprehensive list of tests and procedures counted.

*p*-values were calculated using Chi-squared tests for categorical variables (or Fisher's exact test for sample \<5 patients) and Wilcoxon rank-sum tests for continuous variables.

Age was calculated as of the earliest IBS diagnosis.

See [Supplemental File-Appendix B](https://journals.sagepub.com/doi/suppl/10.1177/1756284818818326) for a comprehensive list of comorbid conditions.

Provided by Area Health Resources Files at the index year. Reference: Area Health Resources Files. <http://ahrf.hrsa.gov/categories.htm>. Data were available for 201,315 patients.

Patients in the high-count group were older (50.6 years) and there was a larger proportion of females (79.5%) compared with the moderate-count (49.5 years and 76.7%, respectively) and zero-count (46.8 years and 74.0%) groups (all *p* \< 0.0001; [Table 1](#table1-1756284818818326){ref-type="table"}). The high-count group also had a higher CCI \[mean 2.2 *versus* 1.4 (moderate-count) and 1.1 (zero-count); all *p* \< 0.0001\] and the highest prevalence of all observed IBS-related comorbidities. Pronounced trends of higher rates of comorbidity associated with higher numbers of tests were observed for dyspepsia (high-count: 13.0%, moderate-count: 5.8%, zero-count: 2.6%; all *p* \< 0.0001), GERD (40.4%, 24.0%, and 15.2%, respectively; all *p* \< 0.0001), constipation (25.6%, 15%, and 7.8%; all *p* \< 0.0001), and depressive disorders (23.5%, 17.7%, and 17.5%; *p* \< 0.0001 for high-count *versus* zero-count and moderate-count). Anxiety was significantly more prevalent in the high-count group (20.4%) compared with the moderate- or zero-count groups (15.5%, and 15.8%; both *p* \< 0.0001 *versus* high-count). Somatization was significantly more prevalent among patients in the high-count group (0.2%) compared with the moderate-count and zero-count group (both 0.1%; both *p* \< 0.0001 *versus* high-count).

### Patient HRU and costs related to IBS {#section13-1756284818818326}

The high-count group had significantly higher mean numbers of annual medical visits to all provider types compared with the moderate-count and zero-count groups, as follows: family practice: 6.5, 4.5, and 3.9, respectively; internal medicine: 5.6, 3.2, and 2.4; gastroenterology: 3.3, 1.4, and 0.4; medical doctor: 3.3, 2.4, and 1.8; multi-specialty physician group: 2.3, 1.6, and 1.2; and emergency medicine: 1.1, 0.4, and 0.3 (all *p* \< 0.0001; [Table 1](#table1-1756284818818326){ref-type="table"}). Furthermore, 66.8%, 11.5%, and 14.4% of the high-count group had at least one gastroenterology visit, ED visit, and inpatient admission, respectively, compared with 49.7%, 4.5%, and 2.8% of the moderate- and 20.6%, 2.0%, 1.5% of the zero-count groups (all *p* \< 0.0001).

The mean number of federal qualified health centers per 100,000 residents, which may indicate a higher standard of care, was lower for the high-count group (3.6) compared with the moderate-count and zero-count groups (both 3.7; all *p* \< 0.0001).

### Multivariable analysis {#section14-1756284818818326}

In the multivariable analyses comparing the demographic and clinical characteristics of the high-count and moderate-count groups, female sex \[OR (CI): 1.1170 (1.0867--1.1481); *p* \< 0.001\], region \[e.g. north-central: 1.1587 (1.1240--1.1946); north-east 1.1239 (1.0806--1.1690); both *p* \< 0.001\], and type of coverage \[HMO: 1.0385 (1.0036--1.0746); *p* = 0.03; comprehensive coverage: 1.1271 (1.0825--1.1737); *p* \< 0.001\] were associated with more frequent (⩾3) tests ([Table 2](#table2-1756284818818326){ref-type="table"}). Age at the index date was statistically associated with fewer tests but had a small effect \[0.9938 (0.9930--0.9947); *p* \< 0.001\]. Patients in areas with more active medical doctors (MDs) per 1000 residents were slightly more likely to have a higher number of tests/procedures \[1.0079 (1.0033--1.0125); *p* \< 0.001\], while patients in areas with more general internal medicine practitioners were slightly less likely \[0.9955 (0.9912--0.9998); *p* = 0.041\]. In addition, patients were slightly less likely to have more tests if they resided in an area with higher proportions of people with a college-level education \[0.9939 (0.9923--0.9956)\] or without a high school-level education \[0.9964 (0.9932--0.9997); *p* = 0.034\].

###### 

Comparison of risk factors among IBS patients stratified by multiple test/procedure counts.^[a](#table-fn10-1756284818818326){ref-type="table-fn"},[b](#table-fn11-1756284818818326){ref-type="table-fn"}^

![](10.1177_1756284818818326-table2)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                  High-count group (⩾3 tests/procedures) *versus*\                                                                                                                           
                                                                                                                                                  Moderate-count group (1--2 tests/procedures)                                                                                                                               
  ----------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------- ---------------------------------------------------------------
  **Demographics**                                                                                                                                                                                                                                                                                                           

   Age^[d](#table-fn13-1756284818818326){ref-type="table-fn"}^                                                                                    1.0047 (1.0041--1.0054)                            \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   0.9938 (0.9930--0.9947)                                 \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   Female                                                                                                                                         1.0620 (1.0366-- 1.0880)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.1170 (1.0867-- 1.1481)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

  **Region**                                                                                                                                                                                                                                                                                                                 

   South                                                                                                                                          1.0738 (1.0522-- 1.0958)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

   North-central                                                                                                                                  1.0661 (1.0422-- 1.0906)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.1587 (1.1240-- 1.1946)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   West                                                                                                                                           0.7533 (0.7339-- 0.7731)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   0.9262 (0.8949-- 0.9586)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   North-east                                                                                                                                     1.1147 (1.0818-- 1.1486)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.1239 (1.0806-- 1.1690)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

  **Insurance plan type**                                                                                                                                                                                                                                                                                                    

   Preferred provider organization                                                                                                                0.9782 (0.9586-- 0.9982)                           0.033[\*](#table-fn8-1756284818818326){ref-type="table-fn"}     [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

   Health maintenance organization                                                                                                                0.8735 (0.8492-- 0.8984)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.0385 (1.0036-- 1.0746)                                0.030[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   Comprehensive coverage                                                                                                                         1.2111 (1.1742-- 1.2492)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.1271 (1.0825-- 1.1737)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   Point of service/point of service with capitation                                                                                              0.9882 (0.9562-- 1.0212)                           0.478                                                           1.0066 (0.9684-- 1.0463)                                0.739

   Consumer-directed health plan/high-deductible health plan                                                                                      1.0412 (0.9710-- 1.1166)                           0.257                                                           1.0168 (0.9394-- 1.1005)                                0.680

   Exclusive provider organization                                                                                                                1.1776 (1.0798-- 1.2842)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.0813 (0.9795-- 1.1936)                                0.121

   Unknown                                                                                                                                        1.0126 (0.9435-- 1.0868)                           0.728                                                           1.0626 (0.9813-- 1.1507)                                0.135

  **Modified Charlson--Quan comorbidity index** ^[a](#table-fn10-1756284818818326){ref-type="table-fn"},\ [@bibr20-1756284818818326]^             1.2707 (1.2630-- 1.2785)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.1452 (1.1365-- 1.1540)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

  **IBS-related comorbidities** ^[a](#table-fn10-1756284818818326){ref-type="table-fn"},[e](#table-fn14-1756284818818326){ref-type="table-fn"}^                                                                                                                                                                              

   Anxiety                                                                                                                                        1.3991 (1.3627-- 1.4366)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.0295 (0.9975-- 1.0625)                                0.071

   Depressive disorders                                                                                                                           1.4267 (1.3914-- 1.4629)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   0.9352 (0.9071-- 0.9641)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   Somatization                                                                                                                                   3.2913 (2.4266-- 4.4642)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.2615 (0.8831-- 1.8021)                                0.202

   Migraines                                                                                                                                      1.5112 (1.4615-- 1.5625)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.1043 (1.0627-- 1.1476)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   Interstitial cystitis                                                                                                                          2.0654 (1.8849-- 2.2633)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.5998 (1.4450-- 1.7711)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   Fibromyalgia                                                                                                                                   1.5809 (1.5327-- 1.6307)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.1150 (1.0759-- 1.1555)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   Chronic fatigue                                                                                                                                1.3272 (1.2341-- 1.4273)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

   Dyspareunia                                                                                                                                    1.5782 (1.4476-- 1.7206)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.3810 (1.2545-- 1.5203)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   Dyspepsia                                                                                                                                      2.4165 (2.3277-- 2.5087)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.7960 (1.7230-- 1.8720)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   GERD                                                                                                                                           2.1440 (2.0972-- 2.1919)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.5933 (1.5542-- 1.6335)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   Constipation                                                                                                                                   1.9531 (1.9032-- 2.0042)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.4967 (1.4538-- 1.5408)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

  **Number of comorbid conditions** ^[e](#table-fn14-1756284818818326){ref-type="table-fn"}^                                                      1.4406 (1.4325-- 1.4488)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

  **Average copayment for medical service (USD)** ^[a](#table-fn10-1756284818818326){ref-type="table-fn"}^                                                                                                                                                                                                                   

   Inpatient                                                                                                                                      1.0011 (1.0010-- 1.0012)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

   Outpatient                                                                                                                                     1.0006 (1.0003-- 1.0010)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

   ED                                                                                                                                             1.0048 (1.0045-- 1.0050)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

   Office                                                                                                                                         1.0013 (1.0007-- 1.0019)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

   Other                                                                                                                                          1.0010 (1.0007-- 1.0012)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

  **Average deductible for medical service (USD)** ^[a](#table-fn10-1756284818818326){ref-type="table-fn"}^                                                                                                                                                                                                                  

   Inpatient                                                                                                                                      1.0007 (1.0007-- 1.0008)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

   Outpatient                                                                                                                                     0.9990 (0.9989-- 0.9991)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

   ED                                                                                                                                             1.0002 (1.0001-- 1.0003)                           0.002[\*](#table-fn8-1756284818818326){ref-type="table-fn"}     [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

   Office                                                                                                                                         0.9922 (0.9917-- 0.9927)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

   Other                                                                                                                                          0.9999 (0.9998-- 1.0000)                           0.009[\*](#table-fn8-1756284818818326){ref-type="table-fn"}     [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

  **Number of medical visits by provider type** ^[a](#table-fn10-1756284818818326){ref-type="table-fn"}^                                                                                                                                                                                                                     

   Family practice                                                                                                                                1.0290 (1.0276-- 1.0304)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.0210 (1.0195-- 1.0226)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   Internal medicine (NEC)                                                                                                                        1.0444 (1.0427-- 1.0461)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.0240 (1.0221-- 1.0260)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   Gastroenterology                                                                                                                               1.2735 (1.2677-- 1.2793)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.2623 (1.2556-- 1.2690)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   Medical doctor (NEC)                                                                                                                           1.0141 (1.0129-- 1.0152)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.0264 (1.0250-- 1.0279)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   Multi-specialty physician group                                                                                                                1.0112 (1.0099-- 1.0126)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.0222 (1.0205-- 1.0239)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   Emergency medicine                                                                                                                             1.2527 (1.2422-- 1.2633)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.0996 (1.0894-- 1.1099)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

  **At least one gastroenterology visit** ^[a](#table-fn10-1756284818818326){ref-type="table-fn"}^                                                2.0351 (1.9936-- 2.0775)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

  **Intestinal-related medical care** ^[a](#table-fn10-1756284818818326){ref-type="table-fn"}^                                                                                                                                                                                                                               

   ED visits                                                                                                                                      2.2831 (2.2047-- 2.3642)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

    *At least one ED visit*                                                                                                                       2.7811 (2.6679-- 2.8991)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.9507 (1.8608-- 2.0449)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   IP admissions                                                                                                                                  4.7579 (4.5452-- 4.9806)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

    *At least one IP admission*                                                                                                                   5.8664 (5.5866-- 6.1602)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   3.6681 (3.4785-- 3.8680)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

  **Federal qualified health centers per 100,000 residents** ^[f](#table-fn15-1756284818818326){ref-type="table-fn"}^                             0.9994 (0.9988-- 1.0000)                           0.067                                                           0.9994 (0.9985-- 1.0002)                                0.156

  **Provider density** ^[f](#table-fn15-1756284818818326){ref-type="table-fn"}^                                                                                                                                                                                                                                              

   Number of hospitals per 100,000 residents                                                                                                      0.9998 (0.9986-- 1.0010)                           0.751                                                           [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

   Number of active MDs per 1000 residents                                                                                                        1.0099 (1.0059-- 1.0139)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   1.0079 (1.0033-- 1.0125)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   Number of gastroenterologists per 1000 residents                                                                                               0.9808 (0.9659-- 0.9961)                           0.014[\*](#table-fn8-1756284818818326){ref-type="table-fn"}     1.0231 (0.9970-- 1.0499)                                0.084

   Number of general internal med per 1000 residents                                                                                              0.9975 (0.9946-- 1.0004)                           0.097                                                           0.9955 (0.9912-- 0.9998)                                0.041[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

  **Neighborhood demographics** ^[f](#table-fn15-1756284818818326){ref-type="table-fn"}^                                                                                                                                                                                                                                     

   % in poverty                                                                                                                                   1.0031 (1.0011-- 1.0051)                           0.002[\*](#table-fn8-1756284818818326){ref-type="table-fn"}     0.9976 (0.9945-- 1.0008)                                0.148

   Median household income (USD)                                                                                                                  1.0000 (1.0000-- 1.0000)                           0.269                                                           [ǂ](#table-fn8-1756284818818326){ref-type="table-fn"}   

   % with college-level education                                                                                                                 1.0003 (0.9993-- 1.0013)                           0.573                                                           0.9939 (0.9923-- 0.9956)                                \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}

   % without high school-level education                                                                                                          0.9965 (0.9946-- 0.9984)                           \<0.001[\*](#table-fn8-1756284818818326){ref-type="table-fn"}   0.9964 (0.9932-- 0.9997)                                0.034[\*](#table-fn8-1756284818818326){ref-type="table-fn"}
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Significant at the 5% level. ǂVariable not selected by stepwise selection procedure.

CI, confidence interval; ED, emergency department; GERD, gastroesophageal reflux disease; IBS, irritable bowel syndrome; IP, inpatient; MD, medical doctor; Med, medicine; N, number; NEC, not elsewhere classifiable; OR, odds ratio; SD, standard deviation; USD, United States dollars.

Evaluated during the 2-year study period which includes the 12 months prior to the earliest IBS diagnosis and the 12 months following the earliest IBS diagnosis.

See [Supplemental File-Appendix A](https://journals.sagepub.com/doi/suppl/10.1177/1756284818818326) for a comprehensive list of tests and procedures counted.

The reported OR, CIs, and *p* values were calculated using logistic regression models. An OR \>1 indicates that exposure associated with higher odds of utilization.

Age was calculated as of the earliest IBS diagnosis.

See [Supplemental File-Appendix B](https://journals.sagepub.com/doi/suppl/10.1177/1756284818818326) for a comprehensive list of comorbid conditions.

Provided by Area Health Resources Files at the index year. Reference: Area Health Resources Files (<http://ahrf.hrsa.gov/categories.htm>). Data were available for 201,315 patients.

Patients with a high CCI score were significantly more likely to have more tests/procedures \[1.1452 (1.1365--1.1540); *p* \< 0.001; [Table 2](#table2-1756284818818326){ref-type="table"}\]. In addition, patients with the following IBS-related comorbidities were significantly more likely to have ⩾3 tests: dyspepsia (1.7960 \[1.7230--1.8720\]), interstitial cystitis \[1.5998 (1.4450--1.7711)\], GERD \[1.5933 (1.5542--1.6335)\], constipation \[1.4967 (1.4538--1.5408)\], dyspareunia \[1.3810 (1.2545--1.5203)\], fibromyalgia \[1.1150 (1.0759--1.1555)\], and migraines \[1.1043 (1.0627--1.1476), all *p* \< 0.001\]. The presence of a depressive disorder was statistically associated with fewer tests but had a small effect \[0.9352 (0.9071--0.9641); *p* \< 0.001\].

The number of visits to the following provider types was associated with a higher test frequency: family practice \[1.0210 (1.0195--1.0226)\], internal medicine \[1.0240 (1.0221--1.0260)\], gastroenterology \[1.2623 (1.2556--1.2690)\], MDs \[1.0264 (1.0250--1.0279)\], multi-specialty physician groups \[1.0222 (1.0205--1.0239)\], and emergency medicine \[1.0996 (1.0894--1.1099); all *p* \< 0.001\]. Patients with ⩾1ED visit \[1.9507 (1.8608--2.0449)\] or inpatient (IP) admission \[3.6681 (3.4785--3.8680); both *p* \< 0.001\] were much more likely to have a higher number of tests/procedures.

### Comparison of IBS-related comorbidity counts among patient groups {#section15-1756284818818326}

Overall, patients with GERD, dyspepsia, dyspareunia, and interstitial cystitis were highly concentrated in the group that received ⩾3 tests/procedures, and there was a trend towards fewer tests as comorbidity burden decreased ([Table 3](#table3-1756284818818326){ref-type="table"}). GERD was the most common comorbidity of the four considered. Of the 57,962 patients with GERD, 58.5% had ⩾3 tests, 29.3% had 1--2 tests, and 12.3% had zero tests. A total of 16,183 patients had dyspepsia, and of these, 67.1% had ⩾3 tests, 25.3% had 1--2 tests, and 7.6% had zero tests. Of the 2647 patients with dyspareunia, 56.4% had ⩾3 tests, 30.3% had 1--2 tests, and 13.3% had zero tests, and of the 2516 patients with interstitial cystitis, the proportions were 63.4%, 26.1%, and 10.6%, respectively.

###### 

Comparison of multiple test/procedure counts among patients with IBS-related comorbidities.^[a](#table-fn17-1756284818818326){ref-type="table-fn"},[b](#table-fn18-1756284818818326){ref-type="table-fn"},[c](#table-fn19-1756284818818326){ref-type="table-fn"}^.
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  IBS-related comorbidities                                 Total patients with comorbidity (*n*)   High-count group, *n* (%)   Moderate-count group, *n* (%)   Zero-count group, *n* (%)                    
  --------------------------------------------------------- --------------------------------------- --------------------------- ------------------------------- --------------------------- --------- ------ ---------
  Dyspareunia                                               2647                                    1494                        (56.4%)                         802                         (30.3%)   351    (13.3%)
  Dyspepsia                                                 16,183                                  10,864                      (67.1%)                         4095                        (25.3%)   1224   (7.6%)
  GERD                                                      57,962                                  33,893                      (58.5%)                         16,964                      (29.3%)   7105   (12.3%)
  Interstitial cystitis                                     2516                                    1594                        (63.4%)                         656                         (26.1%)   266    (10.6%)
  Dyspareunia and dyspepsia                                 295                                     226                         (76.6%)                         62                          (21.0%)   7      (2.4%)
  Dyspareunia and GERD                                      936                                     643                         (68.7%)                         232                         (24.8%)   61     (6.5%)
  Dyspareunia and interstitial cystitis                     186                                     127                         (68.3%)                         40                          (21.5%)   19     (10.2%)
  Dyspepsia and GERD                                        8214                                    6056                        (73.7%)                         1791                        (21.8%)   367    (4.5%)
  Dyspepsia and interstitial cystitis                       257                                     213                         (82.9%)                         36                          (14.0%)   8      (3.1%)
  GERD and interstitial cystitis                            946                                     708                         (74.8%)                         179                         (18.9%)   59     (6.2%)
  Dyspareunia, dyspepsia, and GERD                          169                                     137                         (81.1%)                         30                          (17.8%)   2      (1.2%)
  Dyspareunia, dyspepsia, and interstitial cystitis         30                                      27                          (90.0%)                         3                           (10.0%)   0      (0.0%)
  Dyspareunia, GERD, and interstitial cystitis              74                                      54                          (73.0%)                         13                          (17.6%)   7      (9.5%)
  Dyspepsia, GERD, and interstitial cystitis                150                                     133                         (88.7%)                         14                          (9.3%)    3      (2.0%)
  Dyspareunia, dyspepsia, GERD, and interstitial cystitis   20                                      18                          (90.0%)                         2                           (10.0%)   0      (0.0%)

GERD, gastroesophageal reflux disease; IBS, irritable bowel syndrome.

Evaluated during the 2-year study period which includes the 12 months prior to the earliest IBS diagnosis and the 12 months following the earliest IBS diagnosis.

See [Supplemental File-Appendix B](https://journals.sagepub.com/doi/suppl/10.1177/1756284818818326) for a comprehensive list of comorbid conditions.

See [Supplemental File-Appendix A](https://journals.sagepub.com/doi/suppl/10.1177/1756284818818326) for a comprehensive list of tests and procedures counted.

In addition, the proportions of the high-count, moderate-count, and zero-count groups with two of these four comorbidities were as follows: dyspareunia and dyspepsia (overall *n* = 295; 76.6%, 21.0%, and 2.4%, respectively); dyspareunia and GERD (936; 68.7%, 24.8%, and 6.5%); dyspareunia and interstitial cystitis (186; 73.7%, 21.5%, 10.2%); dyspepsia and GERD (8214; 73.7%, 21.8%, and 4.5%); dyspepsia and interstitial cystitis (257; 82.9%, 14.0%, and 3.1%); and GERD and interstitial cystitis (946; 74.8%, 18.9%, and 6.2%; [Table 3](#table3-1756284818818326){ref-type="table"}). When including patients with three or all of these comorbidities, the proportions were even more greatly skewed towards the high- *versus* the moderate-count or zero-count groups: dyspareunia, dyspepsia, and GERD (overall *n* = 169; 81.1%, 17.8%, and 1.2%, respectively); dyspareunia, dyspepsia, and interstitial cystitis (30; 90.0%, 10.0%, and 0%); dyspareunia, GERD, and interstitial cystitis (74; 73%, 17.6%, and 9.5%); dyspepsia, GERD, and interstitial cystitis (150; 88.7%, 9.3%, and 2.0%); and dyspareunia, dyspepsia, GERD, and interstitial cystitis (20; 90.0%, 10.0%, and 0%; [Table 3](#table3-1756284818818326){ref-type="table"} and [Figure 3](#fig3-1756284818818326){ref-type="fig"}).

![Overall distribution and overlap of patients with IBS and GERD, interstitial cystitis, dyspepsia, and dyspareunia.\
All digits refer to the number of patients with a single or combination of overlapping comorbidities.\
GERD, gastroesophageal reflux disease; IBS, irritable bowel syndrome.](10.1177_1756284818818326-fig3){#fig3-1756284818818326}

Discussion {#section16-1756284818818326}
==========

IBS is a common, chronic and complex GI disorder associated with a significant burden to the healthcare system. The negative financial impact of IBS is related, in part, to the large number of diagnostic tests and procedures performed on IBS patients despite the lack of evidence supporting their need or clinical utility. In this retrospective claims database study of 201,322 patients with IBS, we found that most (41.7%) patients had at least IBS-related diagnostic tests/procedures. After assessing factors associated with frequent use of IBS-related diagnostics tests/procedures, we observed that test/procedure frequency was significantly associated with older age, female sex, GI-related ED or inpatient visits, high overall comorbidity burden, and certain individual comorbidities (GERD, dyspepsia, interstitial cystitis, constipation, and dyspareunia).

Our findings also suggest that the overall health of patients in the high-count group was generally worse than in the others (higher mean CCI) and thus may provide a rationale for the increased number of tests/procedures. Similar to prior studies, we found high comorbidity burden in this population of patients with IBS, particularly anxiety, depressive disorders, and somatization,^[@bibr14-1756284818818326],[@bibr18-1756284818818326],[@bibr21-1756284818818326]^ although these comorbidities were not associated with a higher test frequency. This is important clinically, as it suggests that coexisting anxiety and depression are not driving factors in ordering tests or procedures. In the multivariable analysis, the two comorbidities most strongly associated with a high test frequency were dyspepsia and interstitial cystitis. Dyspepsia and interstitial cystitis are notable in that they involve subjective feelings of abdominal pain, arise from multiple and diverse etiologies, and are often interrelated.^[@bibr22-1756284818818326],[@bibr23-1756284818818326]^ Abdominal pain is a primary predictor of increased HRU among patients with IBS,^[@bibr4-1756284818818326]^ and quality of life is highly associated with patient-perceived IBS severity.^[@bibr24-1756284818818326]^ Our results suggest that abdominal pain arising from multiple overlapping upper and lower abdominal causes (e.g. dyspepsia and IBS and dyspareunia) is a driving factor in providers ordering tests and procedures. The picture that emerges from our study, taken together with prior observations, is one in which functional bowel disorders often present together,^[@bibr25-1756284818818326]^ leading to diagnostic testing approaches that become additive in burden, but not necessarily in benefit.

The current findings have implications for patients, care providers, and payers. Given the lack of consensus on the therapeutic value and clinical utility of tests and procedures in the diagnosis and treatment of IBS, our study indicates that many patients with IBS are subjected to diagnostic tests and procedures which are neither required nor essential or beneficial.^[@bibr6-1756284818818326]^ Unfortunately, this strategy is expensive to both patients and payers,^[@bibr26-1756284818818326]^ and carries significant risks, including adverse events during these procedures. The large proportion of patients receiving multiple tests/procedures over the study period provides strong evidence for the need to increase awareness of physician practice guidelines for the diagnosis and treatment of IBS.^[@bibr9-1756284818818326],[@bibr10-1756284818818326]^ Common practices for IBS management begin with diet and lifestyle modification, and in more severe cases, pharmacotherapy (e.g. antidepressants, smooth muscle antispasmodics, or secretagogues).^[@bibr27-1756284818818326]^ However, in the real world, several studies have noted the high utilization of surgical procedures, related or unrelated to IBS, among patients with IBS.^[@bibr11-1756284818818326][@bibr12-1756284818818326][@bibr13-1756284818818326]--[@bibr14-1756284818818326]^ For example, an analysis of the medical records (1995--2000) of a large cohort of patients with IBS showed that the incidence of abdominopelvic surgery (excluding gallbladder) was 87% higher among these patients *versus* control patients.^[@bibr13-1756284818818326]^

At least one inpatient admission or ED visit was a highly significant risk factor for ⩾3 *versus* 1--2 tests/procedures among this study sample. Prior studies have consistently found that patients with IBS undergo frequent hospitalizations, which appears to be a driver of increased test frequency. For example, a prior survey of HMO participants with IBS found that, over 2 years, these patients had significantly more outpatient and inpatient visits, as well as more ED visits, compared with patients without IBS.^[@bibr26-1756284818818326]^ Similarly, a large managed-care cohort study reported that patients with IBS were more likely than control patients to have blood, stool, endoscopic, and radiologic tests, and to undergo abdominal/pelvic surgery.^[@bibr14-1756284818818326]^ Higher rates of HRU together with higher frequencies of tests (which may be related to inpatient admissions and frequent provider visits) may compound the cost of IBS treatment. The reasons behind the higher HRU among patients with IBS are not well known. Patients with IBS and high levels of somatization are not more likely to seek out GI tests/procedures; however, once they are evaluated for IBS, they expend significantly more healthcare costs compared with matched controls.^[@bibr28-1756284818818326]^ Region of residence has also been reported to impact HRU among IBS patients. A claims database study of HRU in patients with IBS (2001--2012) identified considerable regional variation across the US and noted that 36.3% of patients had ⩾3 different types of GI medical tests/procedures in the a 2-year period surrounding IBS diagnosis.^[@bibr15-1756284818818326]^

In summary, care providers for patients with IBS face a complex decision landscape, where an interplay of underlying patient characteristics, possibly including aspects of their psyche and behaviors, such as their tendency (or not) to seek frequent medical attention, may compound the challenges posed by the presentation of IBS symptoms that frequently overlap with a number of IBS-related comorbidities ([Figure 4](#fig4-1756284818818326){ref-type="fig"}). In the midst of these factors, healthcare professionals have to make cost-effective decisions about appropriate diagnostic tests and interventions, creating a fertile ground that may foster over-testing and redundant procedures.

![Interplay of factors that complicate the full diagnostic process for patients with IBS.\
IBS, irritable bowel syndrome.](10.1177_1756284818818326-fig4){#fig4-1756284818818326}

Future prospective studies could help gain a better understanding of the reasons why diagnostic tests are ordered and evaluate the clinical utility of these tests/procedures regarding the diagnosis and treatment of IBS. This information should strengthen clinical practice guidelines and potentially reduce the economic burden of IBS on the healthcare system. In addition, future studies could expand upon the current analysis by stratifying outcomes by IBS subtype, which could not be performed in this study, as separate ICD-9 codes for IBS subtypes did not exist at the time of data collection.

This study is subject to several limitations. Overall, our study only included patients with IBS and did not provide a matched comparison with a non-IBS reference population. Prior studies have already shown high HRU rates specific to IBS,^[@bibr14-1756284818818326],[@bibr25-1756284818818326]^ and this is a premise that we did not further investigate in our study in the context of diagnostic tests. While we believe that our observations suggest that these patients often undergo excessive testing and are diagnosed by exclusion, an approach inconsistent with the current Rome IV criteria,^[@bibr5-1756284818818326]^ it is true that our study does not close this particular question. A matched comparison to quantify the volume of diagnostic tests with negative results in this population relative to non-IBS individuals would go a long way to more definitively answer the question of whether the excess in diagnostic testing that we observe in IBS patients is truly unwarranted. Given the substantial economic impact of IBS^[@bibr16-1756284818818326],[@bibr29-1756284818818326]^ (a combination of productivity losses, increased interventions and, according to our study, diagnostic procedures), this becomes a pressing question to follow up. There are also specific limitations. First, as with any claims data analysis, this analysis relied on ICD-9-CM and CPT codes to identify diagnoses and procedures within the database, as opposed to actual observance of diagnoses and resource use. However, patients required two separate diagnoses of IBS, which minimizes the possibility of coding errors; in addition, as a byproduct of following the coding system, constipation, which is clinically an IBS symptom (for the disease subtype IBS-C), had to be counted as a comorbidity because IBS subtypes were not coded as such. Second, this study was based on a population of commercially-insured beneficiaries in the US, and the generalizability to other patient populations (e.g. Medicaid, which would include mostly low-income patients younger than 65 years) is unknown. In addition, a large proportion of the included patients were from the southern US (40.5--43.5%), which may limit the representativeness of the sample; race or ethnicity was not included as a variable in the analysis. Third, the results of this study should be interpreted as correlations which may not have causal interpretations. For instance, because tests and hospitalizations were assessed over the same study period, the findings do not imply that hospitalizations or emergency room (ER) visits are associated with future tests that are not directly related to the hospitalization/ER visit; indeed, the association may be mainly due to tests during the hospitalization or ER visit. Or, in another example, we document that patients with higher test counts tend to be older or have higher CCI; it is possible that at least some of those 'excess' tests could be directly driven by those factors, more so than the IBS diagnosis. However, many of the concurrent comorbidities specific to the high-count group were IBS-related and associated with abdominal pain symptoms, an observation that strongly suggests the underlying IBS pathology was an important (and redundant) trigger for a substantial proportion of those tests. Therefore, considering our findings and our study limitations, we are not proposing that clinicians radically curtail diagnostic tests in patients presenting with multiple functional bowel and abdominal symptoms, particularly in elderly patients. We would favor an approach in which clinicians are proactively judicious, weighing all the factors present in a given patient as they decide a diagnostic strategy for them, rather than reacting narrowly to individual symptoms.

Conclusion {#section17-1756284818818326}
==========

This study provides real-world evidence that the frequency of IBS-related diagnostic tests/procedures is strongly associated with a patient's demographic and clinical profile, especially their comorbidity profile. In the clinical setting, healthcare providers equipped with the knowledge that overlapping comorbid conditions of GERD, dyspepsia, and dyspareunia are not just common in IBS patients, but likely explain many of the symptoms reported by IBS patients, should enable clinicians to minimize redundant diagnostic tests and procedures and instead focus on initiating individualized treatment. This should reduce healthcare costs globally and improve patients' quality of life.
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